#USA #Toronto #Isotopia #Kinectrics #Terbium-161

Kinectrics and Isotopia's Innovative Agreement for Gadolinium-160 Supply

In a significant advancement for medical isotope production, Kinectrics has announced a strategic partnership with Isotopia. This collaboration focuses on ensuring a consistent supply of Gadolinium-160 (Gd-160), which is essential for manufacturing Terbium-161 (Tb-161)—a promising agent in radiotherapeutics. As cancer treatment continues to evolve, this agreement aims to address previous limitations in the supply chain of critical isotopes.

The Significance of Gadolinium-160

Gadolinium-160 plays a vital role in the production of Tb-161, which has been garnering attention for its effectiveness in targeting prostate and neuroendocrine tumors. Historically, the limited availability of Gd-160 has hindered progress in clinical trials and the development of therapies. Kinectrics brings a wealth of experience in isotope enrichment, previously excelling with Ytterbium-176 (Yb-176), and is now utilizing its technology to boost the availability of Gd-160.

David Harris, the President and CEO of Kinectrics, expressed his enthusiasm about the new agreement, emphasizing the company's commitment to propelling radiopharmaceutical innovations forward. He stated, "We are extremely pleased to partner with Isotopia in providing the critical isotope Gadolinium-160 to support their production of Terbium-161. After years of research and development as well as significant investment, Kinectrics is proud to be producing highly enriched stable isotopes for the radiopharmaceutical industry. This agreement removes a key bottleneck to advancing Tb-161-based therapies."

Advancements in Terbium-161 Therapy

Dr. Eli Shalom, CEO of Isotopia, highlighted the advantages of Tb-161 in cancer treatments due to its dual mechanism that effectively destroys cancer cells. Specifically, Tb-161's emission of Auger electrons allows precise targeting of micro-metastases, potentially offering superior therapeutic benefits with reduced side effects compared to traditional isotopes like Lu-177. Dr. Shalom emphasized, "This partnership with Kinectrics will enable Isotopia to deliver on its promise to bring Tb-161 to the marketplace and advance our own Tb-161-labeled drug products."

Radiotherapeutics have gained traction in the medical community, providing targeted treatment options that minimize damage to healthy tissues. With the increasing focus on precision medicine, Kinectrics and Isotopia's alliance represents a pivotal moment that could reshape cancer treatment paradigms.

About Kinectrics

Kinectrics is recognized globally for its lifecycle management services within the electricity sector. The firm prides itself on its expertise in engineering and testing, backed by a robust portfolio of facilities and technologies. With over 1,300 engineers and technical specialists, Kinectrics is dedicated to ensuring that utility assets perform safely and efficiently over their lifespan. The company’s membership in the Canadian Nuclear Isotope Council underlines its commitment to nuclear innovation.

About Isotopia

Isotopia Molecular Imaging Ltd. stands at the forefront of medical isotope manufacturing, with production facilities across Israel, Europe, and the United States. Its multidisciplinary team, composed of nuclear pharmacists, radiochemists, and physicists, is dedicated to advancing the development of new imaging markers and molecular therapies. This partnership with Kinectrics will bolster Isotopia's capacity to produce and supply Tb-161, facilitating the next steps toward market availability.

In conclusion, this partnership is set to not only enhance the availability of crucial medical isotopes but also propel the development of advanced cancer therapies. The collaborative efforts from both companies are a promising stride towards improving patient outcomes and advancing the field of radiopharmaceuticals.

Contact Information

• - Kinectrics Contact: [email protected]
• - Isotopia Contact: [email protected]

As medical research continues to transform cancer treatment, such collaborations are essential to harnessing the full potential of advanced therapeutics.